Piper Sandler Reiterates Overweight Rating for Sarepta Therapeutics (NASDAQ:SRPT)

Piper Sandler reaffirmed their overweight rating on shares of Sarepta Therapeutics (NASDAQ:SRPTFree Report) in a research note released on Friday, Benzinga reports. Piper Sandler currently has a $157.00 target price on the biotechnology company’s stock.

A number of other equities research analysts have also recently commented on the stock. Oppenheimer raised shares of Sarepta Therapeutics from a market perform rating to an outperform rating and set a $180.00 target price for the company in a report on Tuesday, May 14th. Mizuho increased their price objective on Sarepta Therapeutics from $145.00 to $179.00 and gave the stock a buy rating in a research report on Friday, May 17th. TheStreet upgraded Sarepta Therapeutics from a d rating to a c- rating in a research note on Monday, March 4th. Citigroup upped their price target on Sarepta Therapeutics from $160.00 to $172.00 and gave the stock a buy rating in a research note on Thursday, February 29th. Finally, BMO Capital Markets reissued an outperform rating and issued a $170.00 price objective on shares of Sarepta Therapeutics in a research note on Friday, June 14th. Four analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of Moderate Buy and a consensus price target of $184.83.

Get Our Latest Report on Sarepta Therapeutics

Sarepta Therapeutics Price Performance

Shares of NASDAQ SRPT opened at $163.85 on Friday. The stock has a market cap of $15.49 billion, a P/E ratio of 1,489.55 and a beta of 0.96. Sarepta Therapeutics has a twelve month low of $55.25 and a twelve month high of $173.25. The stock has a 50 day moving average of $126.47 and a two-hundred day moving average of $120.71. The company has a current ratio of 4.05, a quick ratio of 3.44 and a debt-to-equity ratio of 1.18.

Sarepta Therapeutics (NASDAQ:SRPTGet Free Report) last announced its earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.84. The business had revenue of $413.50 million for the quarter, compared to analysts’ expectations of $375.52 million. Sarepta Therapeutics had a net margin of 1.20% and a return on equity of 2.20%. The company’s quarterly revenue was up 63.1% on a year-over-year basis. During the same period in the previous year, the company posted ($1.44) EPS. On average, research analysts forecast that Sarepta Therapeutics will post 2.99 earnings per share for the current year.

Insider Buying and Selling at Sarepta Therapeutics

In other news, insider Dallan Murray sold 3,635 shares of the business’s stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $140.00, for a total transaction of $508,900.00. Following the sale, the insider now owns 18,125 shares of the company’s stock, valued at approximately $2,537,500. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 7.70% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in SRPT. Envestnet Asset Management Inc. grew its stake in Sarepta Therapeutics by 152.3% in the 3rd quarter. Envestnet Asset Management Inc. now owns 35,642 shares of the biotechnology company’s stock valued at $4,321,000 after acquiring an additional 21,514 shares during the last quarter. Hsbc Holdings PLC grew its position in shares of Sarepta Therapeutics by 26.0% in the third quarter. Hsbc Holdings PLC now owns 2,515 shares of the biotechnology company’s stock valued at $305,000 after purchasing an additional 519 shares during the last quarter. Dark Forest Capital Management LP increased its stake in shares of Sarepta Therapeutics by 65.9% during the 3rd quarter. Dark Forest Capital Management LP now owns 9,228 shares of the biotechnology company’s stock worth $1,119,000 after purchasing an additional 3,666 shares in the last quarter. Northern Trust Corp raised its position in shares of Sarepta Therapeutics by 3.6% during the 3rd quarter. Northern Trust Corp now owns 425,423 shares of the biotechnology company’s stock worth $51,570,000 after purchasing an additional 14,868 shares during the last quarter. Finally, Algert Global LLC lifted its stake in Sarepta Therapeutics by 69.3% in the 3rd quarter. Algert Global LLC now owns 43,182 shares of the biotechnology company’s stock valued at $5,235,000 after buying an additional 17,670 shares in the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

About Sarepta Therapeutics

(Get Free Report)

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

Read More

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.